Unveiling the shield: Troglitazone's impact on epilepsy‐induced nerve injury through ferroptosis inhibition
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14911 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Zhi-Bin Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hos…. Hauptthemen laut MEDLINE: Troglitazone, Epilepsy, Ferroptosis, Neuroprotective Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation, Changsha Municipal Natural Science Foundation, Hunan Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Epilepsy is a widespread central nervous system disorder with an estimated 50 million people affected globally. It is characterized by a bimodal incidence peak among infants and the elderly and is influenced by a variety of risk factors, including a significant genetic component. Despite the use of anti‐epileptic drugs (AEDs), drug‐refractory epilepsy develops in about one‐third of patients, highlighting the need for alternative therapeutic approaches.
Aims
The primary aim of this study was to evaluate the neuroprotective effects of troglitazone (TGZ) in epilepsy and to explore the potential mechanisms underlying its action.
Methods
We employed both in vitro and in vivo models to assess TGZ's effects. The in vitro model involved glutamate‐induced toxicity in HT22 mouse hippocampal neurons, while the in vivo model used kainic acid (KA) to induce epilepsy in mice. A range of methods, including Hoechst/PI staining, CCK‐8 assay, flow cytometry, RT‐PCR analysis, Nissl staining, scanning electron microscopy, and RNA sequencing, were utilized to assess various parameters such as cellular damage, viability, lipid‐ROS levels, mitochondrial membrane potential, mRNA expression, seizure grade, and mitochondrial morphology.
Results
Our results indicate that TGZ, at doses of 5 or 20 mg/kg/day, significantly reduces KA‐induced seizures and neuronal damage in mice by inhibiting the process of ferroptosis. Furthermore, TGZ was found to prevent changes in mitochondrial morphology. In the glutamate‐induced HT22 cell damage model, 2.5 μM TGZ effectively suppressed neuronal ferroptosis, as shown by a reduction in lipid‐ROS accumulation, a decrease in mitochondrial membrane potential, and an increase in PTGS2 expression. The anti‐ferroptotic effect of TGZ was confirmed in an erastin‐induced HT22 cell damage model as well. Additionally, TGZ reversed the upregulation of Plaur expression in HT22 cells treated with glutamate or erastin. The downregulation of Plaur expression was found to alleviate seizures and reduce neuronal damage in the mouse hippocampus.
Conclusion
This study demonstrates that troglitazone has significant therapeutic potential in the treatment of epilepsy by reducing epileptic seizures and the associated brain damage through the inhibition of neuronal ferroptosis. The downregulation of Plaur expression plays a crucial role in TGZ's anti‐ferroptotic effect, offering a promising avenue for the development of new epilepsy treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, P.R. China.
- Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, P.R. China.
- Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, P.R. China.
- Institute of Clinical Pharmacology, Engineering Research Center for Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha, P.R. China.
ORCID-Profile: Zhi-Bin Wang, Xiao-Yuan Mao, Zhao-Qian Liu
Förderung
- China Postdoctoral Science Foundation
- Changsha Municipal Natural Science Foundation
- Hunan Provincial Natural Science Foundation of China
- Major Science and Technology Program of Changsha
- Major Project of Natural Science Foundation of Hunan Province
- National Natural Science Foundation of China
Zitieren
APA
Wang, Z. B., Liu, J. Y., Jiang, S. L., Zhuo, W., Xie, P., Dai, W. T., Mao, X. Y., & Liu, Z. Q. (2024). Unveiling the shield: Troglitazone's impact on epilepsy‐induced nerve injury through ferroptosis inhibition. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14911
Vancouver
Wang ZB, Liu JY, Jiang SL, Zhuo W, Xie P, Dai WT, et al. Unveiling the shield: Troglitazone's impact on epilepsy‐induced nerve injury through ferroptosis inhibition. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14911
BibTeX
@article{Wang2024,
author = {Wang, Zhi-Bin and Liu, Jun-Yan and Jiang, Shi-Long and Zhuo, Wei and Xie, Pan and Dai, Wen-Ting and Mao, Xiao-Yuan and Liu, Zhao-Qian},
title = {Unveiling the shield: Troglitazone's impact on epilepsy‐induced nerve injury through ferroptosis inhibition},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14911}
}
EUVIMED